38 related articles for article (PubMed ID: 19036118)
21. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
23. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
25. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
26. Malignant diseases of the blood.
Haurani FI; Thorling KH
Pa Med; 1966 Nov; 69(11):33-6. PubMed ID: 5342122
[No Abstract] [Full Text] [Related]
27. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
28. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
29. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
30. Tipping the balance: modulating the Wnt pathway for tissue repair.
Zhao J; Kim KA; Abo A
Trends Biotechnol; 2009 Mar; 27(3):131-6. PubMed ID: 19187992
[TBL] [Abstract][Full Text] [Related]
31. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.
Menu E; van Valckenborgh E; van Camp B; Vanderkerken K
Arch Physiol Biochem; 2009 May; 115(2):49-57. PubMed ID: 19234898
[TBL] [Abstract][Full Text] [Related]
32. [Current status in and future directions of the treatment of hematological disorders with molecular-targeting agents--Overview].
Kizaki M
Rinsho Ketsueki; 2011 Aug; 52(8):583-6. PubMed ID: 21897063
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]